Research programme: muscarinic receptor agonists - Mithridion

Drug Profile

Research programme: muscarinic receptor agonists - Mithridion

Alternative Names: CDD-0097; CDD-0098J; CDD-0199J; CDD-0304; CDD-0312; CDD-0313; CDD-0314; CDD-0316; CDD-0317; CDD-0322; MI-10-022

Latest Information Update: 13 Jan 2011

Price : $50

At a glance

  • Originator University of Toledo
  • Developer Mithridion
  • Class Piperidines; Small molecules; Thiadiazoles
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Alzheimer's disease; Schizophrenia

Highest Development Phases

  • Preclinical Alzheimer's disease; Schizophrenia

Most Recent Events

  • 12 Jan 2011 Research programme: muscarinic receptor agonists - Mithridion is available for licensing as of 12 Jan 2011. http://www.mithridion.com
  • 12 Jan 2009 Preclinical development is ongoing for Schizophrenia and Alzheimer's disease in USA
  • 18 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the adverse events and Psychotic Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top